Key Points
- CFO Heather Kiessling sold 80,000 shares on December 18 at an average price of $5.80 for proceeds of $464,000, reducing her stake by 9.85% to 732,500 shares valued at about $4.25 million.
- In the latest quarter ASP Isotopes reported EPS of ($0.15) versus ($0.10) expected and revenue of $4.89 million (beating estimates), but the company remains unprofitable with a deeply negative net margin and return on equity.
- Analyst views are mixed, with price targets ranging roughly $11–$15 and an average target of $13, while MarketBeat’s consensus rating is "Hold" (two Buy ratings and one Sell).
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CFO Heather Kiessling sold 80,000 shares of the company's stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $5.80, for a total transaction of $464,000.00. Following the completion of the transaction, the chief financial officer owned 732,500 shares of the company's stock, valued at approximately $4,248,500. This trade represents a 9.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
ASP Isotopes Price Performance
Shares of ASP Isotopes stock opened at $5.71 on Tuesday. The firm has a market cap of $632.90 million, a PE ratio of -4.39 and a beta of 3.42. ASP Isotopes Inc. has a twelve month low of $3.65 and a twelve month high of $14.49. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04. The business has a 50-day moving average price of $7.31 and a 200 day moving average price of $8.51.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.05). ASP Isotopes had a negative return on equity of 190.44% and a negative net margin of 1,259.12%.The business had revenue of $4.89 million for the quarter, compared to analysts' expectations of $2.25 million. Sell-side analysts predict that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ASP Isotopes
A number of hedge funds have recently modified their holdings of the business. Quantbot Technologies LP acquired a new position in ASP Isotopes during the third quarter worth about $34,000. Ameritas Investment Partners Inc. lifted its stake in ASP Isotopes by 41.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company's stock worth $40,000 after purchasing an additional 1,600 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock worth $41,000 after purchasing an additional 2,548 shares during the last quarter. Close Asset Management Ltd acquired a new position in shares of ASP Isotopes during the 3rd quarter worth approximately $72,000. Finally, Tower Research Capital LLC TRC grew its position in shares of ASP Isotopes by 96.7% in the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company's stock valued at $80,000 after purchasing an additional 5,353 shares in the last quarter. 16.80% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts have weighed in on ASPI shares. Canaccord Genuity Group restated a "buy" rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Monday, November 24th. Loop Capital set a $15.00 target price on shares of ASP Isotopes in a research note on Monday, October 27th. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Monday, December 22nd. Finally, Cantor Fitzgerald initiated coverage on ASP Isotopes in a report on Thursday, December 4th. They issued an "overweight" rating and a $13.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $13.00.
View Our Latest Analysis on ASPI
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
